Login
Login     |     Register     |     Recover Username/Password

General Investing

Commercial Aviation Backlogs Offset Weakness in Defense

June 12, 2012

Although, the short-term outlook appears uncertain for the commercial aerospace and industrial companies, dictated by macroeconomic and political events in Europe and Asia, it looks bright in the longer view, which can be benchmarked by the large commercial airline backlog at the principal aircraft producers, says Richard L. Whittington, a Senior Equity Research Analyst at Drexel Hamilton, LLC.

“It is a split outlook in my estimation. The military-oriented contractors, which have seen very strong business fundamentals for the past decade in the aftermath of the terrorist attacks in 2001, are seeing a picture more dominated by tight government spending and fiscal circumstance,” he said. “It’s more about the backlogs. The backlogs extend, at present rates of production, nearly eight years, which is an unprecedented visibility and duration.”

Whittington likes The Boeing Company (BA) due to the company continuing to push forward on higher rates of production in its key commercial airliner models. He says Boeing should see its commercial profit margins rise 300 to 400 basis points over the next half-dozen years at the same time revenues increase, and that will significantly offset any declines in its military program.

“I see Boeing as a market share gainer within airliners, in general. Its latest model, the 787, should move from a steep loss position over the past couple of years of delay, heavy R&D and expense incursion to make some product fixes to a position of solid profitability, and perhaps, very high profitability late in the decade,” Whittington said.


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now